Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …

Acinetobacter baumannii-calcoaceticus complex (ABC) organisms cause severe infections
that are difficult to treat due to preexisting antibiotic resistance. Sulbactam-durlobactam …

Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …

Background Acinetobacter baumannii is a leading cause of healthcare-associated infections
worldwide, due to both its persistence in the hospital setting and ability to acquire high levels …

Background An urgent need exists for antibiotics to treat infections caused by carbapenem-
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …

Objectives To evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor
durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem …

Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in
development for the treatment of infections caused by Acinetobacter, including multidrug …

ABSTRACT Objectives Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly
strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health …

Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …